Can Serum ICAM 1 Distinguish Pancreatic Cancer from Chronic Pancreatitis?

  • Mohamed, Amal (Department of Medical Biochemistry, National Hepatology and Tropical Medicine Research Institute) ;
  • Saad, Yasmin (Endemic Medicine and Hepatogastroenterology Department, Faculty of Medicine, Cairo University) ;
  • Saleh, Doaa (Community Medicine Department, Faculty of Medicine, Cairo University) ;
  • Elawady, Rehab (Biochemistry Department, Faculty of Pharmacy (Girls), AL- Azhr University) ;
  • Eletreby, Rasha (Endemic Medicine and Hepatogastroenterology Department, Faculty of Medicine, Cairo University) ;
  • Kharalla, Ahmed S. (Department of Microbiology and Immunology, Faculty of Pharmacy, Beni Suif University) ;
  • Badr, Eman (Medical Biochemistry Department, Faculty of Medicine, Menoufia University)
  • Published : 2016.10.01


Background and aim: Pancreatic cancer is the fourth leading cause of cancer-related death worldwide, with an overall 5-year survival of <5% mainly due to presence of advanced disease at time of diagnosis. Therefore development of valid biomarkers to diagnose pancreatic cancer in early stages is an urgent need. This study concerned the sensitivity and specificity of serum ICAM 1 versus CA 19-9 in differentiation between pancreatic cancer and healthy subjects and acohort of patients with chronic pancreatitis with a focus on assessing validity in diagnosis of early stages of pancreatic cancer. Methods: A cohort of 50 patients with histologically diagnosed pancreatic tumors, 27 patients with chronic pancreatitis, and 35 healthy controls were enrolled. Serum samples for measurement of CA19-9 and I-CAM 1 were obtained from all groups and analyzed for significance regarding diagnosis and disease stage. Results: At a cut off value of (878.5 u/ml) I-CAM 1 had 82% and 82.26% sensitivity and specificity for differentiation between cancer and non-cancer cases, with higher sensitivity and specificity than CA19-9 at different cut offs (CA19-9 sensitivity and specificity ranged from 64-80% and 56.4 - 61.2% respectively). The AUC was 0.851 for I-CAM and 0.754 for CA19-9. Neither of the markers demonstrated significance for distinguishing between early and late cancer stages. Conclusion: ICAM 1 is a useful marker in differentiation between malignant and benign pancreatic conditions, and superior to CA19-9 in this regard. However, neither of the markers can be recommended for use in differentiation between early and late stage pancreatic cancers.


Pancreatic cancer;I-CAM;CA19-9;chronic pancreatitis


  1. Alison Ch, Eleftherios PD, Blasutiga IM, et al (2013). Strategies for discovering novel pancreatic cancer biomarkers, J Proteomics, 81, 26 -34.
  2. Ballehaninna UK, Chamberlain RS (2012). The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal, J Gastrointest Oncol, 3, 105-19.
  3. Bosetti C, Lucenteforte E, Silverman DT, et al (2012). Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium, Ann Oncol, 23, 1880-8.
  4. Brand RE, Nolen BM, Zeh HJ, et al (2011). Serum biomarker panels for the detection of pancreatic cancer, Clin Cancer Res, 17, 805-16.
  5. Caliera TAA, Horvath LZ, Zimmermann A, et al (2002). Adhesion molecules in human pancreatic cancer, J Surg Oncol, 79, 93-100.
  6. Fong ZV, Winter JM (2012). Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J, 18, 530-8
  7. Greene FL, Page DL, Fleming ID, et al (2002). Exocrine pancreas, In: AJCC, cancer staging manual, 6th edition, part III, pp 157-61
  8. Kim JE, Lee KT, Lee JK, et al (2004). Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol, 19, 182-6
  9. La Vecchia C (2009). Association between Mediterranean dietary patterns and cancer risk. Nutr Rev, 67, 126-29.
  10. Lamerz R (1999). Role of tumour markers, cytogenetics. Ann Oncol, 4, 145-9.
  11. Liou GY, Doppler H, Necela B, et al (2014). Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. research brief published Online; DOI: 10.1158/2159-8290.CD-14-0474
  12. LiouYG, Doppler H, Necela B, et al (2015). Mutant Kras-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. Cancer Discov, 5, 52-63.
  13. Michaud DS (2004) Epidemiology of pancreatic cancer. Minerva Chir, 59, 99-105.
  14. O'Brien DP, Sandanayake NS, Jenkinson C, et al (2015). Serum CA19-9 is significantly up-regulated up to 2 years prior to diagnosis with pancreatic cancer: implications for early disease detection. Clin cancer .DOI: 10.1158/1078-0432.CCR-14-0365.oncology: First test to monitor pancreatic cancer receives FDA clearance. Cancer Network, 2002.
  15. Richter A, Niedergethmann M, Sturm JW, et al (2003) Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience (link is external). World J Surg, 27, 324-9.
  16. Roland CH, Dineen SP, Toombs JE, et al (2010). Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts, Exp Biol Med, 235, 263-70.
  17. Soliman AS, Zhang Q, Saleh TH, et al (2006). Pancreatic cancer mortality in Egypt: comparison to the United States pancreatic cancer mortality rates. Cancer Detect Prev, 30, 473-9.
  18. Wittel UA, Momi N, Siefert G, et al (2012). The pathobiological impact of cigarette smoke on pancreatic cancer development (Review). Int J Oncol, 41, 5-14.
  19. Yadav D, Lowenfels AB (2013). The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology; 144, 1252-61.
  20. Yang D, Zhu Z, Wang W, et al (2013). Expression profiles analysis of pancreatic cancer. Eur Rev Med Pharmacol Sci, 17, 311-17.
  21. Ziske C, Schlie C, Gorschluter M, et al (2003). Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer, 89, 1413-7.
  22. Zou L, Zhong R, Shen N, et al (2014). Non- linear dose-response relationship between cigarette smoking and pancreatic cancer risk: evidence from a meta-analysis of 42 observational studies. Eur J Cancer, 50, 193-203